A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma

Uterine serous carcinoma (USC) is an uncommon subtype of endometrial cancer with a poor prognosis. USCs have genomic alterations in the PI3K pathway. A prior phase II study of AKT inhibitor MK-2206 (an allosteric AKT inhibitor, primarily affecting AKT1 and AKT2) in endometrial cancers resulted in pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Stover, Elizabeth H., Xiong, Niya, Myers, Andrea P., Tayob, Nabihah, Engvold, Victoria, Polak, Madeline, Broaddus, Russell R., Makker, Vicky, Drapkin, Ronny, Liu, Joyce F., Horowitz, Neil S., Meric-Bernstam, Funda, Aghajanian, Carol, Coleman, Robert L., Mills, Gordon B., Cantley, Lewis C., Matulonis, Ursula A., Westin, Shannon N., Konstantinopoulos, Panagiotis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011027/
https://www.ncbi.nlm.nih.gov/pubmed/35434236
http://dx.doi.org/10.1016/j.gore.2022.100974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011027/
https://www.ncbi.nlm.nih.gov/pubmed/35434236
http://dx.doi.org/10.1016/j.gore.2022.100974

Ejemplares similares